Dr. David K. Gaffney

• 
  www.huntsmancancer.org/annualreport2007/facultyList.htm - [Cached Version]
  Published on: 7/24/2008    Last Visited: 7/24/2008  

  David Gaffney, MD

• 
  www.huntsmancancerinstitute.net/group/breastCancer/team - [Cached Version]
  Published on: 9/11/2008    Last Visited: 9/11/2008  

  David Gaffney, MD, PhD

• 
  www.huntsmancancerinstitute.net/group/radonc/staff.jsp - [Cached Version]
  Published on: 9/11/2008    Last Visited: 9/11/2008  

  David K. Gaffney, MD, PhD

• 
  Bayside Chiropractic - [Cached Version]
  Published on: 2/17/2005    Last Visited: 6/12/2006  

  "Endometrial cancer is the most common gynecological malignancy, and it's treated in a different fashion depending on which area of the country women live," said one of the study's authors, Dr. David Gaffney.He is an associate professor in the department of radiation oncology at Huntsman Cancer Hospital at the University of Utah Medical Center, Salt Lake City.
  
  "There's been a great deal of controversy regarding radiation for stage 1, but in the appropriate subset of patients, a survival benefit was evident in our study," Gaffney added.
  ...
  In an attempt to learn if radiation therapy could provide an additional survival benefit to surgery for women with early endometrial cancer, Gaffney and his colleagues gathered data from the Surveillance, Epidemiology and End Results (SEER) cancer study, conducted between 1988 and 2001.
  
  The database included 21,249 women with stage 1 endometrial cancer.Stage 1 means the cancer is confined to the uterus and hasn't spread to other areas.About 75 percent of women are diagnosed at this stage, according to the National Comprehensive Cancer Network.Staging also includes a letter grade between A and C, which indicates how far into the uterine lining the cancer has progressed, with C indicating the deepest penetration.In addition to being "staged," tumors are also given a grade, and the higher the grade, the more aggressive the cancer is likely to be, according to Gaffney.
  ...
  SOURCES: David Gaffney, M.D., Ph.D., associate professor, department of radiation oncology, Huntsman Cancer Hospital, University of Utah Medical Center, Salt Lake City; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; Jan. 25, 2006, Journal of the American Medical Association

• 
  Cancer Spectrum: Cancer News - This Week's Headlines -... - [Cached Version]
  Published on: 1/25/2006    Last Visited: 6/2/2006  

  David K. Gaffney, M.D., Ph.D., of the Huntsman Cancer Hospital and University of Utah Medical Center in Salt Lake City, and colleagues analyzed data from 1988 to 2001 on 21,249 women with stage 1A-C node-negative endometrial adenocarcinoma in the ongoing Surveillance, Epidemiology, and End Results (SEER).

• 
  Dr. Koop - Radiation Increases Survival for Early... - [Cached Version]
  Published on: 1/25/2006    Last Visited: 1/25/2006  

  "Endometrial cancer is the most common gynecological malignancy, and it's treated in a different fashion depending on which area of the country women live," said one of the study's authors, Dr. David Gaffney.He is an associate professor in the department of radiation oncology at Huntsman Cancer Hospital at the University of Utah Medical Center, Salt Lake City.
  
  Text continued below
  
  >
  
  "There's been a great deal of controversy regarding radiation for stage 1, but in the appropriate subset of patients, a survival benefit was evident in our study," Gaffney added.
  ...
  SOURCES: David Gaffney, M.D., Ph.D., associate professor, department of radiation oncology, Huntsman Cancer Hospital, University of Utah Medical Center, Salt Lake City; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; Jan. 25, 2006, Journal of the American Medical Association

• 
  Huntsman Cancer Foundation - [Cached Version]
  Published on: 1/16/2007    Last Visited: 7/20/2008  

  Women with stage I endometrial cancer (with grade 1 and grades 3 and 4 disease) who receive radiation therapy in addition to other treatment have improved survival rates, according to a study in the January 25 issue of JAMA. (The corresponding or principal author of the study is David Gaffney, M.D., Ph.D., who is medical director of radiation oncology at Huntsman Cancer Institute.)

• 
  Our Cancer Investigators - [Cached Version]
  Published on: 11/13/2006    Last Visited: 8/28/2008  

  David Gaffney, MD, PhD

• 
  Our Physicians - [Cached Version]
  Published on: 9/8/2006    Last Visited: 12/4/2007  

  David Gaffney, MD, PhD
  
  Associate Professor, Department of Radiation Oncology
  
  David Gaffney, MD, PhD, is vice-chair and associate professor of radiation oncology at the University of Utah School of Medicine and Huntsman Cancer Institute.His primary research interests are in the radiotherapeutic management of gynecological cancers, breast cancers, and lymphoma, with a particular focus on prognostic markers for these cancers.
  
  Gaffney is interested in clinical trials that improve survival and quality of life for cancer patients.He serves as chair of the Gynecologic Working Group for the Radiation Therapy Oncology Group (RTOG).The RTOG is a multi-institutional cooperative cancer research organization that conducts clinical trials.He also serves as the chair of the Cervix Working Group of the Gynecologic Cancer Intergroup.This is an international organization interested in the research and treatment of gynecologic neoplasms.Gaffney is the chair of the Clinical Cancer Investigation Committee at the University of Utah and Huntsman Cancer Institute.He is also a member of the American Society for Therapeutic Radiology and Oncology, the American College of Radiology, Utah Medical Association, and multiple other societies.
  
  In addition, Gaffney is interested in radiation sensitizers, which are drugs that make cancer cells more sensitive to the effects of radiation therapy, and in COX-2 inhibitors as anticancer agents.Gaffney is the principle investigator of a RTOG study examining COX-2 inhibitors in cervix cancer treatment.He is involved in a national study of microarray gene expression in cervical cancer before and after chemoradiation.The scientific aspects of the study are being performed at Huntsman Cancer Institute.
  
  Gaffney received his PhD in biochemistry from the Medical College of Wisconsin in 1990 and his MD from the same institution in 1992.He completed an internship at LDS Hospital in Salt Lake City, Utah, and a residency in radiation oncology at the University of Utah School of Medicine.

• 
  Our Physicians - [Cached Version]
  Published on: 11/13/2006    Last Visited: 8/28/2008  

  David Gaffney, MD, PhD, Radiation Oncology

Page:  1 2 3